News

Owlstone Medical Establishes Scientific Advisory Board with Appointment of Professor Sir Bruce Ponder

Owlstone Medical, a diagnostics company developing a breathalyzer for disease, announced today the appointment of Professor Sir Bruce Ponder FRCP FMedSci FRS to its newly established Scientific Advisory Board (SAB) with immediate effect. The SAB will form a key strategic resource, providing unique research perspectives and clinical expertise as the company introduces a new non-invasive diagnostic modality focused on cancer, inflammatory disease and infectious disease.

Professor Sir Bruce Ponder is Emeritus Professor of Oncology at the University of Cambridge and was the inaugural director of the Cancer Research UK Cambridge Institute (CRUKCI). He was knighted for Services to Medicine in the 2008 and was awarded the 2013 Cancer Research UK Lifetime Achievement Prize.

Professor Sir Bruce Ponder has made enormous contributions to the field of oncology, including setting up one of the first specialist clinics for families with cancer, involvement in the discovery of several genes predisposing to cancer, and advances in our understanding of how cancer develops. His group at the CRUKCI is investigating how variations in multiple genes combine to contribute to susceptibility to breast and lung cancer, with the aim to identify high risk groups for targeted cancer screening and prevention.

Billy Boyle, co-founder and CEO at Owlstone Medical, commented: “With over four decades’ work in cancer research we are honoured that Professor Sir Bruce Ponder is joining our SAB. His tremendous depth of experience and knowledge will be hugely valuable to Owlstone Medical as we develop our Breath Biopsy platform for early detection of cancer and realize our ambition to save 100,000 lives and $1.5B in healthcare costs.”

Professor Sir Bruce Ponder added: “There is a great need to detect cancer earlier, and I strongly believe that Owlstone Medical’s technology enabling non-invasive diagnosis through breath can make a big difference in our approach to cancer screening. I am excited to be contributing to the growth and future direction of Owlstone Medical.”

To find out more about Owlstone Medical visit: www.owlstonemedical.com